InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,446.68
(
-1.37%
)
US TECH 100
18,386.40
(
0.00%
)
Dow Jones
40,347.97
(
-1.21%
)
Brent Oil
80.29
(
0.40%
)
Bitcoin
64,182.27
(
-1.79%
)
Post# of 252774
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120193
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: flatlander_60048 post# 96683

Thursday, 06/03/2010 1:48:34 PM

Thursday, June 03, 2010 1:48:34 PM

Post# of 252774
Hi, FL. NVS’ success with Afinitor is in neuroendocrine tumors rather than pancreatic cancer generally. This is a very small market, so it won’t move the needle for a company as large as NVS. Still, Afinitor is an amazing drug when you consider the array of things it does.

Unfortunately, the press release makes it difficult to quantify the results.

The full dataset will be reported as the ESMO conference in October.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up